Passage BIO, Inc.
PASG- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001787297
No open-market purchases or sales by Passage BIO, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Passage BIO, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 68 | 59 | −9 |
| Shares | 37.4M | 35.5M | −1.83M (−4.9%) |
| Value | $51.6M | $34.0M | −$17.5M (−34.0%) |
New holders (5)
Institutions that held Passage BIO, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Tang Capital Management LLC | 300,000 | $287.3K | 0.04% |
| Veritable, L.P. | 23,045 | $22.1K | 0.00% |
| HRT Financial LP | 19,723 | $18.0K | 0.00% |
| Point72 Asset Management, L.P. | 89 | $85 | 0.00% |
| Simplex Trading, LLC | 318 | $0 | 0.00% |
Sold out (14)
Institutions that held Passage BIO, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Rubric Capital Management LP | 822,105 | $1.13M |
| Oasis Management Co Ltd. | 240,000 | $331.2K |
| New York Life Investment Management LLC | 182,978 | $252.5K |
| Bailard, Inc. | 156,900 | $216.5K |
| Bank of Montreal | 49,114 | $70.2K |
| Ergoteles LLC | 37,806 | $52.2K |
| Tri Locum Partners LP | 22,661 | $31.0K |
| Squarepoint Ops LLC | 11,728 | $16.2K |
| Schonfeld Strategic Advisors LLC | 10,000 | $13.8K |
| UBS Group AG | 1,761 | $2.43K |
| Citigroup Inc | 198 | $273 |
| GWM Advisors LLC | 90 | $124 |
| Investors Research Corp | 50 | $69 |
| Northwestern Mutual Wealth Management Co | 20 | $28 |